Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Phenylacetate pharmacokinetics based on iterative two-stage population analysis.

A H Burstein1, E Reed, A C Tompkins

  • 1Clinical Center Pharmacy Department, National Institutes of Health, Bethesda, Maryland, USA.

Pharmacotherapy
|March 20, 2001
PubMed
Summary

This study determined the population pharmacokinetics of phenylacetate in patients with refractory solid tumors. Results suggest previous pharmacokinetic analyses may have been suboptimal.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Commentary: Future of Alzheimer's Disease Treatment: Combination Therapy and Precision Medicine.

The journal of prevention of Alzheimer's disease·2023
Same author

Development of Azeliragon, an Oral Small Molecule Antagonist of the Receptor for Advanced Glycation Endproducts, for the Potential Slowing of Loss of Cognition in Mild Alzheimer's Disease.

The journal of prevention of Alzheimer's disease·2018
Same author

Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus.

Mucosal immunology·2011
Same author

Platinum-DNA adduct in head and neck-cancer patients receiving Cisplatin and Carboplatin chemotherapy.

International journal of oncology·2011
Same author

Partial characterization of a Cisplatin-resistant subline of murine rif-1 tumor-cells.

International journal of oncology·2011
Same author

P53 mutations in egyptian bladder-cancer.

International journal of oncology·2011

Area of Science:

  • Pharmacokinetics
  • Oncology
  • Drug Metabolism

Background:

  • Phenylacetate is used in cancer therapy.
  • Understanding its pharmacokinetic profile is crucial for optimizing treatment.
  • Previous pharmacokinetic evaluations may require refinement.

Purpose of the Study:

  • To determine the population pharmacokinetics of phenylacetate.
  • To implement iterative two-stage analysis using ADAPT 11 software.
  • To refine understanding of phenylacetate pharmacokinetics in patients with refractory solid tumors.

Main Methods:

  • Retrospective pharmacokinetic analysis of 67 patients with refractory solid tumors.
  • Utilized iterative two-stage analysis with ADAPT 11 software.
  • Collected extensive plasma concentration data, with sparse sampling during subsequent therapy courses.

Related Experiment Videos

Main Results:

  • Developed a one-compartment, capacity-limited clearance model for phenylacetate.
  • Estimated key pharmacokinetic parameters including volume of distribution, maximum elimination rate, and Michaelis-Menten constant.
  • Quantified drug clearance induction and its rate of onset.

Conclusions:

  • The determined population pharmacokinetics of phenylacetate align with prior studies.
  • Suggests that earlier pharmacokinetic analyses using the Abbottbase PKS system were suboptimal.
  • Highlights the importance of refined pharmacokinetic modeling for phenylacetate therapy.